Number of the records: 1
PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma – A Pilot Study
- 1.
SYSNO ASEP 0495743 Document Type J - Journal Article R&D Document Type The record was not marked in the RIV Subsidiary J Článek ve WOS Title PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma – A Pilot Study Author(s) Svobodová, Š. (CZ)
Karlíková, M. (CZ)
Topolčan, O. (CZ)
Pecen, Ladislav (UIVT-O) RID, SAI, ORCID
Peštová, M. (CZ)
Kott, O. (CZ)
Treska, V. (CZ)
Slouka, D. (CZ)
Kučera, R. (CZ)Source Title In Vivo - ISSN 0258-851X
Roč. 32, č. 6 (2018), s. 1551-1554Number of pages 4 s. Language eng - English Country NZ - New Zealand Keywords AFP ; PIVKA-II ; biomarkers ; hepatocellular carcinoma ; predictive UT WOS 000447885500035 EID SCOPUS 85055180893 DOI https://doi.org/10.21873/invivo.11413 Annotation Aim: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. Materials and Methods: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). Results: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. Conclusion: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers. Workplace Institute of Computer Science Contact Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800 Year of Publishing 2019
Number of the records: 1